8-K/A - Zura Bio Ltd (0001855644) (Filer)

424B5 - Zura Bio Ltd (0001855644) (Filer)

424B5 - Zura Bio Ltd (0001855644) (Filer)

8-K - Zura Bio Ltd (0001855644) (Filer)

SCHEDULE 13G/A - Zura Bio Ltd (0001855644) (Subject)

SCHEDULE 13G/A - Zura Bio Ltd (0001855644) (Subject)

8-K - Zura Bio Ltd (0001855644) (Filer)

8-K - Zura Bio Ltd (0001855644) (Filer)

8-K - Zura Bio Ltd (0001855644) (Filer)

8-K - Zura Bio Ltd (0001855644) (Filer)

4 - Zura Bio Ltd (0001855644) (Issuer)

4 - Zura Bio Ltd (0001855644) (Issuer)

4 - Zura Bio Ltd (0001855644) (Issuer)

4 - Zura Bio Ltd (0001855644) (Issuer)

4 - Zura Bio Ltd (0001855644) (Issuer)

4 - Zura Bio Ltd (0001855644) (Issuer)

3 - Zura Bio Ltd (0001855644) (Issuer)

4 - Zura Bio Ltd (0001855644) (Issuer)

3 - Zura Bio Ltd (0001855644) (Issuer)

4 - Zura Bio Ltd (0001855644) (Issuer)

3 - Zura Bio Ltd (0001855644) (Issuer)

4 - Zura Bio Ltd (0001855644) (Issuer)

3 - Zura Bio Ltd (0001855644) (Issuer)

4 - Zura Bio Ltd (0001855644) (Issuer)

3 - Zura Bio Ltd (0001855644) (Issuer)

Zura Bio Limited (NASDAQ:ZURA) ("Zura"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that it closed its previously announced underwritten public offering of Class A ordinary shares and pre‑funded warrants on February 26, 2026. The offering consisted of 21,200,000 Class A ordinary shares priced at $6.25 per share, along with pre‑funded warrants for 1,800,000 Class A ordinary shares priced at $6.249 per warrant, which included 3,000,000 additional Class A ordinary shares sold upon exercise in full by the underwriters of th

Zura Bio Limited (NASDAQ:ZURA), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the pricing of its previously announced underwritten public offering of 18,200,000 Class A ordinary shares at a price to the public of $6.25 per share and, in lieu of Class A ordinary shares to certain investors that so choose, pre-funded warrants to purchase 1,800,000 Class A ordinary shares at a price to the public of $6.249 per pre-funded warrant, which equals the public offering price per Class A ordinary share, less the $0.001 exercise price o

Zura Bio Limited (NASDAQ:ZURA), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that it has commenced an underwritten public offering of its Class A ordinary shares or, in lieu of Class A ordinary shares to certain investors that so choose, pre-funded warrants to purchase Class A ordinary shares. In addition, Zura expects to grant the underwriters a 30-day option to purchase additional Class A ordinary shares in an amount of up to 15% of the aggregate number of shares and shares underlying the pre-funded warrants sold in the o

Zura Bio Limited (NASDAQ:ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the appointments of Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to its Board of Directors, effective February 21, 2026. As part of this transition, Neil Graham, M.B.B.S., M.D., M.P.H., will step down from the Board effective the same date. "Mark and Ajay are accomplished immunology executives who have successfully guided innovative biologics from early development through approval and commercialization on a

Zura Bio Limited (NASDAQ:ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that its senior leadership team will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on Wednesday, February 11, 2026, at 11:00 AM ET in New York, NY. The Company will also conduct one-on-one investor meetings on the same day. A live webcast of the presentation will be available in the Investors section of the Company's website under News & Events. A replay will remain archived for at lea

Zura Bio Limited (NASDAQ:ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the appointment of Sandeep Kulkarni, M.D. as Chief Executive Officer (CEO), effective January 21, 2026. Dr. Kulkarni will also continue serving as a Director of Zura. Dr. Kulkarni succeeds Kim Davis, J.D., who has served as Interim CEO since October 2025 following the commencement of a medical leave of absence by CEO Robert Lisicki. Mr. Lisicki is resigning as CEO and as a Director, effective as of January 21, 2026. Ms.

2026 begins as a transformative year for Zura with potential clinical validation of tibulizumab as a groundbreaking therapy in hidradenitis suppurativa (HS) Expanded Phase 2 TibuSHIELD trial in HS expected to deliver topline data in the fourth quarter of 2026 Zura maintains a strong financial position with cash expected to fund planned operations through 2027, beyond the data readouts in both HS and systemic sclerosis (SSc) Zura Bio Limited (NASDAQ:ZURA) ("Zura"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported busine

Continued advancement of two Phase 2 clinical trials evaluating tibulizumab in hidradenitis suppurativa (HS) (TibuSHIELD) and systemic sclerosis (SSc) (TibuSURE), with topline data expected in the second half of 2026. Reported $139.0 million in cash and cash equivalents as of September 30, 2025, which is expected to fund planned operations through 2027. Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio" or the "Company"), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported financial results for the third quarter ended September 30, 2025, and provided recent corporate and pipeline updates. "Both t

Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio" or the "Company"), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet needs, today announced that its senior leadership team will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference on Thursday, September 4, 2025, at 2:45 PM ET in New York, NY. The Company will also conduct one-on-one investor meetings on the same day. A live webcast of the presentation will be available in the Investors section of the Company's website under News & Events. A replay will remain archived for at least 30 days. ABOUT ZURA BIO Zura Bio is a

Initiated TibuSHIELD, a global Phase 2 clinical study evaluating tibulizumab in adults with moderate to severe hidradenitis suppurativa (HS) in Q2 2025 Continued progress in the Phase 2 TibuSURE clinical study evaluating tibulizumab in adults with systemic sclerosis (SSc) Appointed new executive and board leadership to support ongoing growth and development Reported $154.5 million in cash and cash equivalents as of June 30, 2025; expected to fund planned operations through 2027 Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio" or the "Company"), a clinical-stage, multi-asset immunology company dedicated to developing novel dual-pathway antibodies for autoimmune and inflammatory diseas

Wedbush initiated coverage of Zura Bio Limited with a rating of Outperform and set a new price target of $15.00

Leerink Partners initiated coverage of Zura Bio Limited with a rating of Outperform and set a new price target of $15.00

H.C. Wainwright initiated coverage of Zura Bio Limited with a rating of Neutral and set a new price target of $5.00

Piper Sandler initiated coverage of Zura Bio Limited with a rating of Overweight and set a new price target of $26.00

Ladenburg Thalmann initiated coverage of Zura Bio Limited with a rating of Buy and set a new price target of $10.00

Oppenheimer initiated coverage of Zura Bio Limited with a rating of Outperform and set a new price target of $17.00

Guggenheim initiated coverage of Zura Bio Limited with a rating of Buy and set a new price target of $20.00

Chardan Capital Markets initiated coverage of Zura Bio Limited with a rating of Buy and set a new price target of $14.00

Raymond James initiated coverage of Zura Bio Limited with a rating of Strong Buy and set a new price target of $20.00

Achieved key milestones in 2024 that enhanced our leadership team, strengthened our financial position, and progressed our clinical pipeline Initiated the Phase 2 TibuSURE trial in adults with systemic sclerosis (SSc) Completed a $112.5 million private placement financing in April 2024, contributing to a total of $176.5 million in cash and cash equivalents, as of December 31, 2024 Cash runway anticipated through 2027, supporting operations and funding anticipated tibulizumab data readouts in SSc and hidradenitis suppurativa (HS) Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio" or the "Company"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for

Expect to initiate Phase 2 studies evaluating tibulizumab for the treatment of systemic sclerosis (SSc) in Q4 2024 and hidradenitis suppurativa (HS) in Q2 2025 Cash, cash equivalents and investments totaling $188.2 million as of September 30, 2024, are anticipated to support operations, as currently planned, through 2027 Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported financial results for the third quarter of 2024 and recent corporate updates. "In the third quarter of 2024, we made significant progress toward initiating our first Phase 2 tria

Initiating Phase 2 clinical trials in 2024 to evaluate ZB-106 (tibulizumab) in systemic sclerosis and hidradenitis suppurativa, and ZB-168 in alopecia areata Experienced team building the next Immunology leader Cash position of $103.9 million in cash, cash equivalents and investments is expected to support development and operations into 2026 Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio") a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced its financial results for the quarter ended September 30, 2023, and recent business highlights. "In the third quarter, Zura Bio made significant progress

Focused on advancing ZB-106, a potential first-in-class anti-IL-17 and anti-BAFF dual antagonist for systemic sclerosis and hidradenitis suppurativa Experienced team building the next immunology leader Cash and cash equivalents of $113 million support development and operations through 2026 Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio" or the "Company"), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced its financial results for the second quarter ended June 30, 2023, and recent business highlights. "Zura Bio made great progress in the first half of 2023, and we look forward to advancing

SC 13G/A - Zura Bio Ltd (0001855644) (Subject)

SC 13G/A - Zura Bio Ltd (0001855644) (Subject)

SC 13G - Zura Bio Ltd (0001855644) (Subject)

SC 13G/A - Zura Bio Ltd (0001855644) (Subject)

SC 13G/A - Zura Bio Ltd (0001855644) (Subject)

SC 13G - Zura Bio Ltd (0001855644) (Subject)

SC 13G - Zura Bio Ltd (0001855644) (Subject)

SC 13G/A - Zura Bio Ltd (0001855644) (Subject)

Zura Bio Limited (NASDAQ:ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the appointments of Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to its Board of Directors, effective February 21, 2026. As part of this transition, Neil Graham, M.B.B.S., M.D., M.P.H., will step down from the Board effective the same date. "Mark and Ajay are accomplished immunology executives who have successfully guided innovative biologics from early development through approval and commercialization on a

Zura Bio Limited (NASDAQ:ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the appointment of Sandeep Kulkarni, M.D. as Chief Executive Officer (CEO), effective January 21, 2026. Dr. Kulkarni will also continue serving as a Director of Zura. Dr. Kulkarni succeeds Kim Davis, J.D., who has served as Interim CEO since October 2025 following the commencement of a medical leave of absence by CEO Robert Lisicki. Mr. Lisicki is resigning as CEO and as a Director, effective as of January 21, 2026. Ms.

Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases, today announced the appointment of Eric Hyllengren as Chief Financial Officer, effective July 7, 2025. He will succeed Verender Badial, who will step down from the role and remain with the company as a non-executive employee through July 31, 2025, to support a seamless transition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250701021645/en/Eric Hyllengren Mr. Badial joined Zura Bio in March 2023, at the time of its business combination with

Presented data for tibulizumab at EULAR 2024, highlighting the potential relevance of dual-inhibition of both IL-17A and BAFF in autoimmune and inflammatory diseases Expect to initiate Phase 2 studies evaluating tibulizumab for the treatment of systemic sclerosis (SSc) in 4Q 2024 and hidradenitis suppurativa (HS) in 2Q 2025 Strengthened management and advisory team with appointment of Robert Lisicki as CEO & formation of Scientific Advisory Board Cash, cash equivalents and investments of $188.4 million as of June 30, 2024, including $112.5 million from private placement executed in April 2024, anticipated to support operations as currently planned through 2027 Zura Bio Limited

Significant 2023 milestones highlighted by successful Nasdaq listing, leadership team buildout, formation of strategic development and scientific plan On track to initiate Phase 2 study evaluating tibulizumab (ZB-106) for the treatment of systemic sclerosis (SSc) in 2H 2024 Appointment of CEO, Robert Lisicki, underscores Zura Bio's commitment to building leading immunology company as we prioritize excellence in strategic development and scientific planning Outgoing Founder and CEO, Someit Sidhu, M.D., will continue as a Board Director to leverage institutional knowledge and provide continued support Cash position as of December 31, 2023 totaling $99.8 million in cash, cash equi

Accomplished biopharmaceutical executives bring invaluable expertise and experience to Zura Bio's Clinical Development programs Executive Leadership hires position Zura Bio for Phase 2 clinical trial readiness across multiple indications in 2024 Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced the appointments of Robert Lisicki as President and Chief Operating Officer, and Kiran Nistala, MBBS, PhD, as Executive Vice President Development and Chief Medical Officer, to the Executive Leadership Team. Mr. Lisicki will be responsible for developing an

Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, announced the Board of Directors appointed Arnout Ploos van Amstel as Non-Executive Independent Director by way of co-optation. Mr. Ploos van Amstel replaces Dr. Garry Neil who will continue to support Zura Bio as an advisor on R&D matters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231114200703/en/Arnout Ploos van Amstel (Photo: Business Wire) With a career spanning over three decades in the global biotech and pharmaceutical sector, Mr. Ploos van Amstel

Zura Bio Limited (Nasdaq: "ZURA") ("Zura Bio"), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced the appointment of Michael D. Howell, Ph.D., to the role of Chief Scientific Officer and Head of Translational Science. Dr. Howell brings more than two decades of experience leading discovery, translational research, and early clinical programs and will lead the scientific strategy and translational science efforts at Zura Bio. "I am thrilled to have Michael Howell join our team as our Chief Scientific Officer and Head of Translational Science," said Someit Sidhu, M.D., CEO of Zura Bio. "He brings ov